Skip to Main Content

Associate Christopher Ferenc Comments on IPR Proceedings in BioPharm Insight

Firm News | March 27, 2014

Christopher Ferenc, an associate in the Intellectual Property practice, spoke with BioPharm Insight regarding inter partes review (IPR) proceedings, which employ a different set of standards than litigation since they lack the presumption of validity. Christopher notes that from the perspective of a patent challenger, IPR proceedings could therefore make patents easier to invalidate. (“Lilly Could Attempt Inter Partes Review Route to Hasten Insulin Glargine Approval in Legal Action Against Sanofi – Attorneys,” February 27, 2014)

Katten Websites   Careers  |  Alumni  |  Mobile Site
Contact Us   Offices  |  Media Center  |  People  |  Email
Legal Notices   Disclaimer  |  Privacy Notice  |  Cookie Notice  |  United Kingdom Notices  | Accessibility 
© 2019 Katten Muchin Rosenman LLP